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Abstract
Hepatic encephalopathy (HE) or portosystemic encephalopathy (PSE) is a 
serious neuropsychiatric disorder resulting from liver failure. It is one of the com-
mon complications of liver cirrhosis and portosystemic shunting (PSS). Ammonia 
accumulation is one of the well-established causes. Ammonia is a by-product of the 
intestinal bacteria as a result of the breakdown of dietary supplements. In the nor-
mal state of the liver, the peripheral hepatocyte contains glutaminase that converts 
glutamine into glutamate and ammonia; ammonia will be detoxified and converted 
into urea. The variant manifestations were linked to the severity of HE. A wide 
range of neurological and psychiatric signs have been reported. The International 
Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) uses 
asterixis (i.e., flapping tremor) as the first clinical sign of HE. Four factors should 
be taken into consideration to classify and distinguish HE from other conditions: 
HE type, severity of manifestations following West-Haven Criteria (WHC), HE 
time course, and presence of precipitating factors. Nonabsorbable disaccharides 
(lactulose and lactitol) and rifaximin have been the standard of care as first- and 
second-line therapies, respectively. Non-pharmacological interventions had a 
crucial role in HE management. Liver transplantation is the ultimate management 
of hepatic cirrhosis.
Keywords: liver cirrhosis complications, hepatic encephalopathy, hepatic stupor, 
hepatic coma, portosystemic encephalopathy, hepato-cerebral encephalopathy, 
hyperammonemia, pharmacotherapy
1. Introduction
Hepatic encephalopathy (HE) or portosystemic encephalopathy (PSE) is a seri-
ous neuropsychiatric disorder resulting from liver failure [1]. It is a state of abnor-
mal neurological manifestations ranging from subclinical alterations to coma. It can 
be classified into three types based on underlying etiology. It is one of the common 
complications of liver cirrhosis and portosystemic shunting (PSS). HE accounts 
for 62% mortality rate among cirrhotic patients over 3 years [2]. A description of 
HE clinical state is as old as the Prognostics and Prosthetics of Hippocrates [3]. 
The association between jaundice and delirium was linked to cirrhosis as early as 
the seventeenth century [3]. In the absence of preexisting disease, acute, severe 
liver failure may cause the brain to swell, with patients becoming comatose and 
losing brain function altogether. Hepatic encephalopathy in patients with chronic 
liver disease is revocable and controllable, but new, acute (fulminant) hepatic 
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encephalopathy with speedily mounting blood ammonia values is harder to control 
due to the diffuse brain edema as well as structural brain-stem injury [4, 5].
Although HE is linked to liver cirrhosis, multifactorial complex pathogenesis is 
involved but not fully understood.
2. Epidemiology
Over a year, 5 to 7% of cirrhotic patients progress from a compensated state 
to decompensated stage [4]. The progression of the disease reduces survival by 
10 years, with life expectancy around 12 years in patients with compensated 
liver cirrhosis that drop to 2 years in decompensated end-stage liver disease [4]. 
Mortality rate among patients in end-stage liver disease was 20% over 1 year. HE 
is one of the definitions of decompensated liver disease [5]. The incidence of overt 
HE ranges from 10 to 14% at the time of diagnosis and increases up to 21% at 
decompensated state and up to 50% in patients post transjugular intrahepatic por-
tosystemic shunt (TIPS). Overall, up to 4% of cirrhotic patients will have HE state 
sometimes during the disease course. Once the patient develops the first episode of 
HE, the risk of recurrence increases up to 40% within a year from the first episode 
[5]. After the first episode of HE, the survival rate at 1 and 3 years was 73% and 
38%, respectively [2].
3. Pathophysiology
The exact pathophysiology of HE has not been entirely understood with multi-
ple mechanisms identified as pathological etiologies of HE. Ammonia accumulation 
is one of the well-described causes [6]. Ammonia is a by-product of the intestinal 
bacteria as a result of the breakdown of dietary supplements. In the normal state of 
the liver, the peripheral hepatocyte contains glutaminase that converts glutamine 
into glutamate and ammonia; ammonia will be detoxified and converted into urea, 
a product that is easily excreted by the kidneys. In case of liver cirrhosis, ammonia 
accumulates and is shifted into the systemic circulation leading to the activation 
of other detoxifying pathways (e.g., skeletal muscle, kidney, and brain). However, 
overtime ammonia will accumulate [6]. Neurotoxins that prevent the transmis-
sion of amino acids and electrolytes across the brain membrane is known [6]. The 
impact of ammonia on the neurons is directly linked to HE manifestations. This is 
one of the most targeted mechanisms for HE treatment. At high levels, ammonia 
will be able to penetrate the blood-brain barrier. Subsequently, glutamine is formed 
when astrocytic glutamine synthetase converts ammonia and glutamate. This in 
turn acts as an osmolyte and increases cerebral volume.
Nevertheless, other pathways have been identified including the gamma-
aminobutyric acid (GABA), neurosteroids, inflammation, oxidative stress, manga-
nese, zinc deficiency, and intestinal microflora [6]. Further research is needed to 
understand the magnitude of these factors in HE prognosis and the possibility of 
targeting those pathways in future therapies.
4. Clinical presentation
The variant manifestations were linked to the severity of HE. A wide range of 
neurological and psychiatric signs have been reported. The International Society for 
Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) uses asterixis  
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(i.e., flapping tremor) as the first clinical sign of HE [7]. The neurological symp-
toms might be mild to the extent of being undetectable to noticeable behavioral 
changes progressing to coma. HE may affect psychology, memory, visuospatial 
ability, and brain electrophysiology [8]. Hence, a series of manifestations are seen 
including but not limited to apathy, irritability, sleep-wake cycle disturbance, dis-
orientation to time and place, hypertonia, and extrapyramidal dysfunction [9]. It is 
worth mentioning that none of these manifestations is HE pathognomonic finding.
5. Diagnosis and classification
The wide range of clinical manifestations necessitates a consensus diagnostic 
and classification criteria. Four factors should be taken into consideration to classify 
and distinguish HE from other conditions [5]: first, HE type (i.e., Type A resulting 
from acute liver failure, Type B resulting from PSS, and Type C resulting from liver 
cirrhosis); second, severity of manifestations where the most commonly used are 
West-Haven Criteria (WHC) with five grades (Table 1 Minimal to Grade IV) and 
ISHEN criteria with two categories (covert and overt HE); third, HE time course: 
classified into episodic, recurrent (i.e., within 6 months or less), and persistent; and 
fourth, the presence of precipitating factors (e.g., infections, electrolyte disorder, 
gastrointestinal bleeding, transjugular intrahepatic portosystemic shunt). In 
clinical practice settings, WHC is the most useful tool to identify clinical descrip-
tion, but it should be correlated with the case scenario. Multiple neurological and 
psychometric clinical tests (e.g., portosystemic encephalopathy, critical flicker 
frequency, and inhibitory control test) have been developed to early identify mini-
mal and covert HE (MHE and CHE), but it needs expert examiner to appropriately 
interpret results.
Ammonia level alone cannot be used as a sole diagnostic indicator, and it should 
be assessed within the clinical context. However, if the level is normal, the HE 
diagnosis is less likely [5]. Computed tomography (CT) scanning of the head could 
be performed to rule out structural considerations in the differential diagnosis, 
including intracranial hemorrhage. However, for patients with well-documented 
liver disease, it might not be necessary.
6. Management
The principle of HE management involves several steps. Those include airway 
protection (for patients presenting with coma), treat or prevent precipitating 
Grade Criteria
Grade 0 Lack of detectable changes in personality or behavior, no asterixis
Grade 1 Trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance 
of addition, and asterixis may present
Grade 2 Lethargy or apathy, minimal disorientation for time or place, inappropriate behavior, subtle 
personality, slurred speech, impaired performance of subtraction
Grade 3 Somnolence to semistupor but responsive to verbal stimuli, confusion, gross disorientation, and 
asterixis is usually absent
Grade 4 Coma (unresponsive to verbal or noxious stimuli)
Table 1. 
West-Haven Criteria (WHC) [2, 5].
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factors, analyze and treat other causes of altered mental status (e.g., hyponatremia, 
diabetes, thiamin deficiency, intracranial bleeding), and provide pharmacological 
and non-pharmacological treatments. Different approaches are used to either treat 
or prevent HE.
6.1 Non-pharmacological treatment and prevention
6.1.1 Protein restrictions
Protein restriction is one of the components of managing patients with HE. As 
result, cirrhotic patients have higher prevalence of malnutrition [10]. During 
episodes of overt HE, protein restriction is advised. Once symptoms of HE are 
resolved, protein intake can be resumed: range 1–1.5 g/kg/day coupled with other 
therapies. This should be coupled with maintaining energy intakes at 35–40 kcal/kg 
ideal body weight daily [5].
Protein source may also play a role in management of HE. Vegetable protein 
with higher fiber content may be preferable to animal protein as it decreases colonic 
putrefaction [11, 12]. Animal protein contains high amounts of aromatic amino 
acids; those amino acids can work as substrates to neurotransmitter’s tyramine and 
octopamine, are thought to inhibit dopaminergic neurotransmission, and worsen 
hepatic encephalopathy [11, 12].
6.1.2 Fecal transplant and probiotics
Fecal microbiota transplant was also reported to have beneficial outcomes 
reversing the intestinal microbial dysbiosis [13]. Additionally, probiotics have been 
used as secondary prophylaxis of HE, either as natural probiotics or in a pharma-
ceutical dosage form [14, 15].
6.1.3 Liver transplantation and artificial support system
Non-pharmacological interventions have a crucial role in HE management. Liver 
transplantation is the ultimate management of hepatic cirrhosis [5]. However, the 
complexity and challenges of such approach reduce the feasibility of transplanta-
tion. Other interventions may improve overall liver function, e.g., balloon-occluded 
retrograde transvenous obliteration, taking into consideration the applicability of 
each procedure on case-by-case manner [16]. Nevertheless, artificial liver support 
system was reported to have positive impact on overall liver cirrhosis complications, 
including HE [17, 18].
6.2 Pharmacological treatment and prevention
6.2.1 Non-absorbable disaccharides (lactulose and lactitol)
Lactulose is considered as the first-line therapy and has been in medical use 
since the 1950s. It is a form of synthesized fructose sugar containing galactose 
and lactose, while lactitol is a synthetic alcohol sugar consisting of lactose and 
sorbitol. It has been in the pharmaceutical market since 1987. As non-absorbable 
nutrients, the normal flora degradation of lactulose or lactitol leads to the 
reduction in PH toward acidic media in the colon. It will convert ammonia (NH3) 
into ammonium (NH4) that enhances a shift in NH3 concentration and hence the 
movement from the blood to the intestine. This will reduce the ammonia level 
from dietary and endogenous source (Table 2). Nevertheless, they act as osmotic 
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laxatives that increase water into the intestines and stimulate a bowel move-
ment. Over the years, lactulose and lactitol are used to treat constipation and 
hyperammonemia. A systematic review assessing the impact of non-absorbable 
disaccharides on HE outcomes resulted in the inclusion of 22 randomized clinical 
trials (RCT) evaluating either lactulose or lactitol, neither showing significant 
difference in clinical outcomes including HE improvement and mortality [19]. 
Few years later, another systematic review was conducted. They included 38 RCT 
assessing the effect of either lactulose or lactitol in HE treatment and prevention. 
There was no significant difference between the two agents, but both of them 
had a beneficial effect on HE, including serious liver-related adverse events (e.g., 
variceal bleeding, serious infections, and hepatorenal syndrome), HE recurrence, 
and overall mortality [20]. The continuation on non-absorbable disaccharides 
beyond the treatment period had a positive impact on HE recurrence [21, 22]. 
Generally, both lactulose and lactitol have preferable safety profile and low 
burden from cost perspectives. However, non-favorable effects such as hyper-
natremia, hypokalemia, and gastrointestinal side effects have been reported. 
In lactose-intolerant patients, such side effects might be more pronounced. 
Polyethylene glycol (PEG) is a promising alternative, but further studies are 
needed to have robustness positive outcomes of PEG in HE management [23]. For 
all osmotic laxatives used in HE, two to four bowel motions per day as targeted 
outcome of therapy used to adjust doses and avoid side effects. Initial dose of 
25 mL lactulose given orally every 1–2 hours until the patient has two bowel 
motions or loose stool can be adjusted accordingly [5]. Continuation on therapy 
reduces the risk of recurrent HE episode as long as the risk of lactulose overuse 
is monitored (e.g., dehydration, hypernatremia, severe perianal skin irritation, 
and even precipitating HE) [5]. No difference between oral and rectal as route 
of administration, however, based on the clinical context, one of them might be 
preferable over the other (e.g., comatose patient) [24].
6.2.2 Antibiotics
Antibiotics’ role in HE management fills within the inhibition of ammonia-
producing colonic bacteria. Rifaximin is a poorly absorbed bactericidal antibiotic 
(rifamycins). It is available in the market since 2004, and the Food and Drug 
Administration (FDA) approval for patients with liver disease was obtained in 
2010. Rifaximin has a wide-spectrum antibacterial activity including anaerobic 
species. Local action of rifaximin inhibits the bacteria protein synthesis via binding 
to RpoB inhibiting the function of DNA-dependent RNA polymerase. At dose of 
550 mg PO twice daily, it was effective in HE treatment and prevention of recurrent 
episode. However, it was used as add-on therapy where majority of participants 
Therapeutic agents* Mechanism of action Role in 
therapy
Nonabsorbable 
disaccharides (lactulose 
and lactitol)
Normal flora degradation of lactulose or lactitol leads to the reduction 
in PH toward acidic media in the colon. It will convert ammonia (NH3) 
into ammonium (NH4) that enhances a shift in NH3 concentration and 
hence the movement from the blood to the intestine
First-line 
therapy
Rifaximin Local action of rifaximin inhibits the bacteria protein synthesis via 
binding to RpoB inhibiting the function of DNA-dependent RNA 
polymerase
Add-on 
therapy
*Other therapies do not have a clear role in treatment and can be considered on a case-by-case basis.
Table 2. 
Recommended pharmacological treatment [5].
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were using lactulose [25, 26] (Table 2). Different antibiotics have been used in 
HE management including neomycin, metronidazole, and vancomycin [27]. 
Neomycin is an aminoglycoside with controversy outcomes regarding its efficacy in 
HE. Antibacterial activity and glutaminase inhibition are the proposed mechanisms 
of neomycin effect in HE [27]. In attempt to find safer, effective, and more tolerable 
alternative, both metronidazole and vancomycin have been studied. Oral metroni-
dazole is used with success, yet peripheral neuropathy may occur with long-term 
therapy. Limited studies were conducted in patients with poor response to lactulose 
monotherapy and showed improved response [27]. Although the FDA approved 
it, taking into consideration the safety profile of those agents (e.g., ototoxicity and 
neurotoxicity) and the risk of resistance development favors rifaximin over other 
antibiotics, although peripheral edema, central nervous system (CNS) side effects, 
and gastrointestinal intolerance have been reported with rifaximin. Published data 
on rifaximin cost-effectiveness showed that rifaximin alone was not cost-effective. 
Hence, it is not recommended as first-line therapy. However, in patients who are not 
responding to lactulose/lactitol, the addition of rifaximin may reduce hospitaliza-
tion and prevent recurrence [28–30]. The availability of a generic rifaximin may 
change the cost-effectiveness outcomes.
6.2.3 L-ornithine-L-aspartate (LOLA)
The efficacy of intravenous L-ornithine L-aspartate (LOLA) as monotherapy in 
MHE was assessed in a RCT; it showed improved ammonia level and mental states 
[31]. In a meta-analysis of eight randomized trials with 646 patients in total, LOLA 
had a significant effect on improvement of hepatic encephalopathy total (RR, 1.49; 
95% confidence interval [CI], 1.10 to 2.01) and overt HE (RR, 1.33; 95% CI, 1.04 to 
1.69) [32]. LOLA has not been compared directly to active treatment  
(e.g., lactulose).
6.2.4 Glycerol phenylbutyrate (GPB)
Metabolic ammonia scavengers (e.g., benzoate, phenyl acetate, and glyceryl 
phenylbutyrate) have been used in genetic disorders involving urea cycle. Such 
disorders result in hyperammonemia, and such therapeutic agents may exert a 
possible treatment option [33]. In a randomized, double-blind, placebo-con-
trolled phase II trial enrolling 178 patients with cirrhosis (including patients who 
were on lactulose ± rifaximin), GPB, dosed at 6 mL orally twice daily, signifi-
cantly reduced the proportion of patients who experienced an HE event (21% 
versus 36%; P = 0.02), time to first event (hazard ratio [HR] = 0.56; P < 0.05), 
as well as total events (35 versus 57; P = 0.04) and was associated with fewer HE 
hospitalizations (13 versus 25; P = 0.06) [33]. Further trails are still required to 
validate the results. Moreover, the current cost of the drug may still be a barrier to 
its use at a larger scale.
6.2.5 Branched-chain amino acids (BCAA)
Branched-chain amino acids (BCAA) classified into proteinogenic (i.e., leucine, 
isoleucine, and valine) and non-proteinogenic (i.e., 2-aminoisobutyric acid) are 
essential amino acids. In limited clinical trials, BCAA had a beneficial impact on HE 
outcomes in addition to standard therapy. However, this positive effect was limited 
to oral dosage forms but not the intravenous formulation. BCAA had no impact on 
mortality, quality of life, or nutritional parameters; additional trials to evaluate 
such outcomes are needed [34–36].
7Pharmacotherapy of Hepatic Encephalopathy
DOI: http://dx.doi.org/10.5772/intechopen.84348
6.2.6 Zinc supplementation
Zinc deficiency is common in cirrhotic patients. In case of documented defi-
ciency, oral zinc supplementation can improve performance, but it did not affect 
the risk of recurrence [37]. Hyperammonemia could improve with zinc administra-
tion as it increases the activity of ornithine transcarbamylase, an enzyme in the 
urea cycle. Afterward, the increase in ureagenesis leads to the loss of ammonia ions. 
Further studies are needed to understand the possible role of micronutrient supple-
mentation on long-term HE outcomes.
6.2.7 Flumazenil
Flumazenil is an antidote to reverse benzodiazepine toxicity by competitively 
binding to the benzodiazepine receptor site. Symptoms of benzodiazepine toxicity 
may overlap with HE (e.g., confusion, anxiety, and unresponsiveness). Flumazenil 
can be used as a diagnostic aid to differentiate between the two conditions [5].
6.2.8 Other therapies
Other therapies have not been assessed extensively in HE management (e.g., 
albumin and glutaminase inhibitors). Such alternatives had promising outcomes 
encouraging further research in this area. Albumin intravenous administration did 
not impact HE directly but improved survival post-discharge [38]. Glutaminase 
inhibition is a promising target of drug therapy in HE management. It could be a 
new era of research that may change HE management principle but nothing solid 
yet [39].
L-Carnitine was found to improve HE symptoms in several small studies of 
patients with cirrhosis. The exact mechanism remains unclear. One of the proposed 
mechanisms is that it may work by improving blood ammonia levels or centrally 
perhaps by decreasing brain ammonia uptake [40].
Dopamine agonists (e.g., levodopa or bromocriptine) are shown to result in 
improvement in clinical and electroencephalographic findings in anecdotal reports 
and small studies. If these results are confirmed at larger studies, it may lead to 
clinical recommendations.
7. Conclusion
HE is a reversible clinical syndrome with a wide range of manifestations, which 
will negatively impact patient quality of life if mismanaged. Different management 
approaches have been developed. The most appropriate treatment should be applied 
on case-by-case fashion.
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